



Pulse NeedleFree Systems Receives Funding to Expand R&D for Human Health Devices

LENEXA, KANSAS, February 23, 2011 – Pulse NeedleFree Systems today announced that it has received a grant from the Kansas Bioscience Authority to expand and accelerate development of its human health needle-free technology.

Pulse's injection system is the only needle-free delivery device in development that is cost-competitive with conventional syringes. The system is specifically designed to serve the needs of large-scale immunization programs. The World Health Organization estimates that unsafe injections, needle-sticks and improperly disposed needles cause over 1 million early deaths each year.



This funding was awarded under the Kansas Bioscience Authority's Proof of Concept program, which provides funding to Kansas bioscience organizations for key phases of research and development. This grant follows the award that Pulse recently received under the U.S. Federal Qualifying Therapeutic Discovery Program. Earlier phases of the technology development were supported through collaborations with the Seattle-based Program for Appropriate Technology in Health, through funding from the Bill and Melinda Gates Foundation.

"We are very excited to expand our needle-free device research and development through this funding from the KBA and Heartland BioVentures," said James R. Smith, Chairman of Pulse NeedleFree Systems. "This is an important step towards commercializing our unique technology and meeting a large unmet need in the vaccine industry."

About Pulse NeedleFree Systems: Pulse NeedleFree Systems, Inc., founded in 2001, is a privately-held medical device technology firm. As the leading supplier of innovative needle-free injection technology to the animal health segment, Pulse is applying its technological expertise to enter the human health medical device market. The Pulse technology propels liquid through a small orifice to create an injection stream that penetrates skin without the need for an invasive and painful needle. Pulse's corporate headquarters and research facilities are located in Lenexa, Kansas, a suburb of Kansas City. More information can be found on Pulse's website at <http://www.pulse-nfs.com>.

About Kansas Bioscience Authority: The Kansas Bioscience Authority is a \$581-million initiative created by the Kansas Economic Growth Act of 2004 to expand the state's world-class research capacity and bioscience clusters; support the growth of bioscience startups; and stimulate bioscience business expansion and attraction. More information can be found on the KBA's website at <http://www.kansasbioauthority.org>.